US$16 million = AU$23 million
RGS marketcap only 37 million
No upfront costs for RGS.
US $5.5 mil in RGS pocket immediately.
Another US $16 mill to enter into rgs pocket throughout development.
Continual royalty and licencing revenue for both parties.
Our multinational partner to cover all costs of manufacturing.
Our multinational partner has access and connections with major biopharmas in japan and globally.
As aruc6393 mention above.